% | $
Quotes you view appear here for quick access.

Array BioPharma Inc. Message Board

  • dcaf7 dcaf7 Feb 25, 2013 8:58 AM Flag

    Selumetinib in BRAF and NRAS mutated melanoma

    The results will be presented at AACR 2013
    Abstract Number: 2284
    Presentation Title: Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma
    Presentation Time: Monday, Apr 08, 2013, 4:20 PM - 4:35 PM
    Location: Room 207, Washington Convention Center
    Author Block: Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunc Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman. Memorial Sloan Kettering Cancer Center, New York, NY

3.23-0.15(-4.44%)Aug 24 4:00 PMEDT